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Abstract 
Background: This study aimed to evaluate, longitudinally, the outcome of periodontal regenerative therapy using a 
deproteinized bovine bone mineral (DBBM) in combination with a collagen barrier (CB) for the treatment of intrabony 
defects.
Results: Patients with chronic periodontitis who have completed initial periodontal therapy participated in this 
study. They had at least one 2- or 3-wall intrabony periodontal defect of ≥3 mm in depth. During surgery, defects 
were filled with DBBM and covered with CB. Ten patients completed 2.5-year reevaluation. At baseline, mean clini-
cal attachment level (CAL) of the treated site was 8.0 mm and mean probing depth (PD) was 7.5 mm. Mean depth of 
intrabony component was 4.6 mm. Mean gains in CAL at 6 months and 2.5 years were 2.8 ± 1.0 and 1.4 ± 1.5 mm, 
respectively, both showing a significant improvement from baseline. CAL gains at 1 and 2.5 years were significantly 
reduced from that at 6 months. A significant improvement in PD was also noted: mean reductions in PD at 6 months 
and 2.5 years were 4.0 ± 0.8 and 3.2 ± 0.8 mm, respectively.
Conclusions: The combination therapy using DBBM and CB yielded statistically significant effects such as CAL gain 
and PD reduction, up to 2.5 years in the treatment of intrabony defects. However, the trend for decrease in CAL gain 
over time calls for the need for careful maintenance care.
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Background
Periodontitis is an inflammatory disease of tooth sup-
porting tissues induced by plaque biofilm [1] and also 
considered as a dysbiotic disease with an adverse effect 
on systemic health [2]. In the treatment of periodontitis, 
initial periodontal therapy consisting of plaque control 
and scaling and root planing is the fundamental non-sur-
gical treatment. In cases of moderate to advanced peri-
odontitis, surgical interventions are often necessary.
Guided tissue regeneration (GTR) is defined as ‘a sur-
gical procedure with the goal of achieving new bone, 
cementum, and periodontal ligament attachment to a 
periodontally diseased tooth, using barrier devices or 
membranes to provide space maintenance, epithelial 
exclusion, and wound stabilization’ [3]. GTR has been 
successfully used for the regeneration of periodontal tis-
sues for more than three decades [4]. For the treatment 
of intrabony defects (periodontal defect within the bone 
surrounded by one, two or three bony walls or combina-
tion of thereof ), especially those with uncontained con-
figuration (1 or 2 wall) or  ≥3-mm width, combination 
GTR therapy is recommended [5]. Various bone graft 
materials can be used with barrier membranes [6, 7]. 
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GTR using a deproteinized bovine bone mineral (DBBM) 
combined with a collagen barrier (CB) membrane has 
been reported to yield more gains in clinical attachment 
level (CAL) than flap operation alone [8, 9]. Furthermore, 
the combination therapy demonstrated a significantly 
more periodontal regeneration than each individual com-
ponent [10, 11]. Although these GTR therapies yielded 
clinically favourable results, a substantial degree of vari-
ability in the outcome has been reported with a marked 
center effect [6, 12, 13], and longitudinal data are still 
limited. Furthermore, according to the practice guideline 
by the Japanese Society of Periodontology, the evidence 
for added benefit of the combination GTR therapies is 
not yet sufficient [14].
Previously, we conducted a series of prospective mul-
ticenter studies of the GTR using a DBBM (Bio-Oss®, 
Geistlich Pharma AG, Switzerland) and a non-cross-
linked CB (Bio-Gide®, Geistlich) in the treatment of 
intrabony defect, and reported that the combined use of 
the DBBM and CB yielded a significant gain in CAL and 
reduction in probing depth (PD) at 6  months following 
surgery [15, 16]. We hypothesized that the favourable 
clinical outcome can be sustained for longer period of 
time, following this combination therapy.
This study aimed to assess 2.5-year clinical outcome of 
periodontal regenerative therapy using DBBM in combi-
nation with CB in the treatment of intrabony defects in 
patients with chronic periodontitis.
Methods
Study design and participants
This study presents a subset of patients who were treated 
at Tokyo Dental College Chiba Hospital, Chiba, Japan as 
part of a multicenter study [16]. The original study was con-
ducted as a prospective non comparative 6-month study, 
performed at five centers; four private practices special-
ized in periodontics in Tokyo, Japan, and one dental school 
clinic. The participants were recruited from patients with 
chronic periodontitis [17] from April 2013 to February 
2014. This study was performed in accordance with the 
Helsinki Declaration, and the protocol was approved by the 
ethics committee of Tokyo Dental College (No.431). Writ-
ten informed consent was obtained from all participants.
Inclusion and exclusion criteria
Inclusion criteria consisted of having at least one 2- or 
3-wall intrabony defect  ≥3  mm in depth in interproxi-
mal area of teeth, interproximal sites with probing depth 
(PD) ≥6 mm, keratinized gingiva ≥2 mm, and good level 
of oral hygiene [mean plaque index (PlI) ≤1] [18]. Par-
ticipants must have completed initial periodontal therapy 
consisting of plaque control and consecutive sessions of 
quadrant scaling and root planing within 3 months.
Systemic exclusion criteria were the presence of uncon-
trolled systemic diseases, smokers, allergy to collagen, 
concurrent or previous bisphosphonate, high dose cor-
ticosteroid or other drug therapy, current pregnancy or 
lactation and general contraindications for dental and/or 
surgical treatment. Those under 20 years old or with fur-
cation involvements at target teeth are also excluded.
Clinical examination
The following parameters were recorded by trained, cali-
brated examiners at baseline: after recording of gingival 
index (GI) [19] and PlI, PD and gingival recession (GR) 
were recorded in 0.5  mm increments using a pressure-
sensitive periodontal probe (Gram Probe #2, YDM, 
Higashi Matsuyama, Japan). CAL was calculated as the 
sum of PD and GR. Bleeding on probing (BOP) was 
recorded as the presence or absence of bleeding following 
measurement of PD. Tooth mobility (TM) [20] was also 
recorded. Reevaluations were performed at 6 months, 1 
and 2.5 years after surgery.
Radiographic assessment
Semi-standardized radiographs were taken with the long 
cone paralleling technique using film holders (CID-3, 
Hanshin Technical Laboratory, Nishinomiya, Japan) with 
customized occlusal stents.
Surgical procedures
The surgical intervention was implemented as 
described previously [16]. Briefly, following local infil-
tration anaesthesia, defects were accessed using the 
modified papilla preservation technique [21] or the 
simplified papilla preservation flap [22]. After removal 
of granulation tissue, scaling and root planning was 
performed. No root surface conditioning was used. 
Then the defects were filled with DBBM (Geistlich Bio-
Oss®, 0.25–1  mm, Geistlich Pharma AG, Wolhusen, 
Switzerland), which had been pre-soaked in sterile 
saline. A porcine-derived non-cross-linked CB mem-
brane (Geistlich Bio-Gide®, Geistlich Pharma AG) was 
then placed to cover the bone graft material and defect 
margin. No sutures were used to stabilize the CB. The 
flaps were then replaced to obtain full closure and 
sutured by modified vertical mattress and interrupted 
sutures using e-PTFE sutures (Gore-Tex® Suture CV-6, 
W.L. Gore and Associates, Flagstaff, AZ, USA). No per-
iodontal dressing was used.
Intrasurgical measurements
The following parameters were assessed after debride-
ment of the area: (1) distance from the cemento-enamel 
junction (CEJ) to the bottom of the defect (CEJ-BD); (2) 
distance from the CEJ to the most coronal extension of 
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the interdental bone crest (CEJ-BC). These measure-
ments were performed at the deepest interdental point of 
the defect and recorded in 0.5 mm increments. The intra-
bony component of the defect (INTRA) was calculated as 
INTRA = (CEJ-BD) − (CEJ-BC).
Postsurgical care
The patients received antimicrobial agents (typically 
cefdinir 300  mg/d, for 4  days). Standard analgesic was 
given as needed. Patients were instructed to rinse twice 
daily with an antimicrobial mouth rinse (Listerine® Fresh 
Mint, Johnson & Johnson, Tokyo, Japan) and to use the 
following oral hygiene procedures in the treated area for 
the first 4 postoperative weeks. The patients were asked 
to start gentle wiping of the operated dento-gingival area 
with an ultra-soft toothbrush from the third postopera-
tive day. No interdental cleaning in the treated area was 
allowed during the first 4 weeks.
The sutures were removed after 14  days. Professional 
supragingival tooth cleaning was performed at weeks 1, 2 
and 4. Thereafter, all patients were placed on the mainte-
nance programs.
Maintenance care
Following completion of the original 6-month study, the 
patients were assigned to maintenance or supportive per-
iodontal therapy based on individual needs. They were 
asked to come in at 3-month intervals as appropriate. 
At these appointments, the patients’ oral hygiene status 
and periodontal conditions were evaluated and the oral 
hygiene procedures were reinforced as necessary. Scal-
ing and professional tooth cleaning were performed as 
needed.
Statistical analysis
At each visit, data were recorded in a case report form. 
After proofed for entry errors, the data were compiled 
by creating a computerized file. The primary outcome 
variable was the change in CAL. In the calculations, 
measurements at the same deepest point of the selected 
defect were included. CAL gain and PD reduction were 
also summarized as percentage changes from baseline 
values.
Repeated measures analysis of variance with Tukey–
Kramer multiple comparisons test or Friedman test with 
Dunn’s multiple comparisons test was used to analyze 
changes in quantitative data over time. Comparisons for 
BOP data were made by Fisher’s exact test. Correlation 
between variables was analyzed by Spearman rank cor-
relation. A software package (InStat version 3.10 for Win-
dows, GraphPad Software, La Jolla, CA, USA) was used. 
A p value of less than 0.05 was considered statistically 
significant.
Results
Study participants and baseline clinical parameters
Out of 19 Japanese patients at Tokyo Dental College who 
have completed the original 6-month study [16], 10 patients 
(mean age 55.5 years old, 5 women and 5 men) were avail-
able for the follow-up 2.5 years post-treatment. The reasons 
for drop-outs were patient no-shows and appointment can-
cellations for transferring to a different dental clinic or for 
unknown reasons. Demographic information and clinical 
parameters at baseline are presented in Table 1.
Each participant contributed one defect site. Treated 
teeth comprised 3 (30% of treated sites) incisors (2 maxil-
lary, 1 mandibular), 1 (10%) canine (maxillary), 3 (30%) 
premolars (2 maxillary, 1 mandibular) and 3 (30%) molars 
(3 mandibular). The mean width of keratinized tissue was 
4.9 mm. The mean value for INTRA was 4.6 mm.
Change in clinical parameters
All participants had received systemic antimicrobial agents, 
analgesics and mouth rinse as instructed. The postoperative 
healing was generally uneventful. Throughout the study, 
none of the participants underwent any adverse event.
At 6 months after surgery, a significant improvement in 
CAL from baseline was observed (p < 0.001) (Fig. 1a). A 
significant improvement from baseline was also observed 
at 1 year (p < 0.01) and at 2.5 years (p < 0.05). The CAL 
values at 1 and 2.5  years were significantly greater than 
that at 6  months (p  <  0.01). The mean gains in CAL 
(primary outcome variable) at 6  months and 2.5  years 
were 2.8  ±  1.0  mm (range: 1.0  mm to 4.0  mm) and 
1.4 ±  1.5  mm (range: −1  mm to 4.0  mm), respectively. 
Table 1 Patient demographics and  clinical parameters 
at baseline
CAL clinical attachment level, PD probing depth, GR gingival recession, PlI plaque 






Age (years; mean ± SD) 55.5 ± 14.8 (range, 28–76)
Sex (% women) 50
CAL (mm; mean ± SD)a 8.0 ± 1.2 (range, 6.0–10.0)
PD (mm; mean ± SD)a 7.5 ± 1.1 (range, 6.0–9.5)
GR (mm; mean ± SD)a 0.7 ± 0.9
PlIa 0.1 ± 0.1
GIa 0.6 ± 0.3
BOP positive (%)a 80
TMb 0.6 ± 0.5
Width of keratinized tissue  
(mm; mean ± SD)b
4.9 ± 1.7 (range, 3.0–8.0)
INTRA (mm; mean ± SD)c 4.6 ± 1.3 (range, 3.0–7.0)
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Percentages of CAL gains at 6 months and 2.5 years were 
35.5 and 17.0%, respectively.
Distribution of CAL change values at 2.5 years is shown 
in Fig.  1b. Seven participants showed CAL gains and 
three showed CAL losses or no change.
As for the secondary outcome variables, a significant 
improvement in PD was noted at 6 months, 1 and 2.5 years 
(Fig.  2a). No significant differences in PD values were 
observed between 6  months, 1 and 2.5  years. The mean 
reductions in PD at 6 months and 2.5 years were 4.0 ± 0.8 
and 3.2 ± 0.8, respectively. Percentages of PD reductions at 
6 months and 2.5 years were 53.0 and 42.3%, respectively. 
There was a gradual increase in GR from baseline to 1 year 
after surgery (Fig. 2b). A significant difference from base-
line in GR values was observed at 1 and 2.5 years (p < 0.01). 
However, no significant difference between 1 and 2.5 years 
was noted. Compared to 6 months, contribution of GR to 
the reduction in PD was greater at 2.5 years (Fig. 3). 
As expected, baseline values for PlI, GI, and TM were 
relatively low, because the participants have already 
received initial periodontal therapy. A further, signifi-
cant reduction in GI from baseline was found at 1 and 
2.5 years (Table 2). No significant differences in PlI and 
Fig. 1 Change in CAL. a Mean CAL values at each evaluation period. 
Data shown as mean ± SD (n = 10). *P < 0.05, **P < 0.01, ***P < 0.001, 
compared to baseline, ††P < 0.01, compared to 6 months, by ANOVA 
with Tukey–Kramer multiple comparisons test. b Distribution of 
individual CAL change from baseline at 2.5 years. Dotted line indicates 
the mean value. CAL clinical attachment level
Fig. 2 Change in PD (a) and GR (b). Data shown as mean ± SD 
(n = 10). **P < 0.01, ***P < 0.001, compared to baseline, by ANOVA 
with Tukey–Kramer multiple comparisons test. PD probing depth, GR 
gingival recession
Fig. 3 Contribution of GR and CAL gain to PD reduction. Mean val-
ues are shown. GR gingival recession, CAL clinical attachment level
Table 2 Change in PlI, GI, and TM
Data shown as the mean ± SD (n = 10)
PlI plaque index, GI gingival index, TM tooth mobility
** P < 0.01, significantly different from baseline, by Friedman test with Dunn’s 
multiple comparisons test
Variable Baseline 6-month 1-year 2.5-year
PlI 0.1 ± 0.1 0.2 ± 0.4 0.3 ± 0.3 0.3 ± 0.3
GI 0.6 ± 0.3 0.1 ± 0.2 0.03 ± 0.1** 0.1 ± 0.1**
TM 0.7 ± 0.5 0.4 ± 0.5 0.4 ± 0.5 0.5 ± 0.5
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TM were found during the observation periods. As for 
BOP, a significant difference from baseline was noted at 
2.5 years (Table 3).  
Relationship between baseline variables and CAL gain or 
PD reduction at 2.5 years
No significant correlation was found between CAL gain 
at 2.5 years and baseline variables (Table 4). PD reduction 
at 2.5  years was significantly positively correlated with 
baseline PD and INTRA, indicating that the deeper the 
initial PD or INTRA, the greater tends to be PD reduc-
tion after surgery.
A representative case is shown in Fig. 4.
Discussion
In the present study, we evaluated longitudinally the 
clinical outcome of periodontal regenerative therapy 
using DBBM in combination with CB in the treatment of 
intrabony defects in Japanese patients with chronic peri-
odontitis. The combination therapy yielded statistically 
significant gains in CAL and reductions in PD at 2.5 years, 
when compared with the preoperative values. However, 
the trend for decrease in CAL gain over time was noted. 
These results should be interpreted with caution in terms 
of their clinical relevance.
A meta-analysis study has indicated that combina-
tion regenerative therapies performed better than the 
single therapies, although the additional benefits were 
small [23]. In the present study, significant PD reductions 
from baseline were sustained up to 2.5 years, and no sig-
nificant difference in PD was observed between 6 months 
Table 3 Change in BOP
BOP bleeding on probing
* P = 0.023, by Fisher’s exact test (two-sided)
a Percent sites positive
Variable Baseline 6-month 1-year 2.5-year
BOPa 80 40 30 20*
Table 4 Correlations between baseline valuables and CAL 
gain or PD reduction at 2.5 years
r, Spearman coefficient. Significant differences are indicated in italics
CAL clinical attachment level, PD probing depth, TM tooth mobility, INTRA 
intrabony component
Baseline variable CAL gain PD reduction
r P r P
CAL 0.341 0.330 −0.408 0.245
PD −0.047 0.892 −0.816 0.006
TM 0.191 0.584 0.120 0.733
INTRA 0.273 0.448 0.719 0.023
Patient age −0.207 0.560 0.114 0.759
Fig. 4 A representative treatment case. 42-year-old woman. a Before surgery (baseline), in the mesial aspect of the maxillary right canine; PD 
6.0 mm, CAL 7.0 mm (top). In the radiograph, vertical bone defect is observed (bottom). b During surgery, careful scaling and root planing was per-
formed after removal of granulation tissue (top). Then the defect was filled with DBBM (middle) and covered with CB (bottom). c Postoperative views 
at 6 months, d 1 year, e 2.5 years; PD 2.0 mm, CAL 3.0 mm (top). In the radiograph, an improvement in the initial bone defect area can be observed 
(bottom)
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and 2.5  years. As for the CAL gain, the mean value was 
1.4 ±  1.5  mm at 2.5  years after the combination therapy. 
The value was significantly smaller than that obtained 
at 6  months (2.8 ±  1.0  mm). Moreover, the CAL gain at 
2.5  years is smaller than the values in the previous stud-
ies of combination regenerative therapies with longer 
observation periods. In a case-series of 15 patients, Stav-
ropoulos and Karring [24] showed the mean CAL gain of 
4.1 ± 1.3 mm at 5Y after the GTR therapy using the DBBM 
in combination with PLA/PGA bioabsorbable membrane. 
In their randomized clinical trial [25], the mean CAL gain 
of 2.3 ± 2.1 mm was noted in 10 patients at 6Y after the 
same combination therapy. In a randomized controlled 
study, Sculean et  al. [26] demonstrated the CAL gain of 
3.7 ± 1.1 mm in 10 patients at 5 years after the same combi-
nation therapy as the present study. The mean CAL gain in 
the present study was also smaller than the values observed 
in our previous studies of different regenerative thera-
pies. In our 5-year clinical evaluation of GTR using a non-
resorbable membrane only [27], the mean CAL gain was 
3.6 mm, and another study using the enamel matrix deriva-
tive (EMD) showed the value of 3.4  mm at 2  years [28]. 
Even among studies using the same materials, it is difficult 
to directly compare clinical results because of the differ-
ences in the skill of surgeons, incision and flap designs and 
baseline CAL or PD values of the participants. For example, 
the baseline mean PD in the study by Sculean et al. [26] was 
9.1 mm whereas the value for our study was 7.5 mm. It has 
been reported that a greater gain in CAL can be expected 
after regenerative therapy, in patients with greater initial 
values in PD and CAL [29, 30], although no significant cor-
relation was found between the CAL gains at 2.5 years and 
baseline PD or CAL values in the present participants.
In the present study, two participants showed CAL 
losses at 2.5  years from baseline (−1.0 and −0.5  mm), 
although they both had CAL gains of  ≥3.0  mm at 
6  months. Given the small number of participants, 
these negative values contributed to the relatively mod-
est mean CAL gains observed at 2.5  years. Moreo-
ver, at 2.5 years, seven out of 10 participants showed a 
decrease in CAL gain values from 6 months. It is nota-
ble that the mean PD of the participants at 6  months 
was 3.5 mm, which is somewhat greater than the value 
(2.7  mm) reported in our previous study using EMD 
[28]. These data may indicate the need for more meticu-
lous postoperative maintenance care in the present par-
ticipants. A partial loss of the CAL gain obtained 1 year 
after GTR has been shown to be associated with smok-
ing, compromised oral hygiene [31], and poor compli-
ance with a supportive periodontal program [32, 33]. All 
participants were asked to follow 3-month recall, but 
some (including those with CAL loss) failed to comply 
with this, resulting in longer maintenance intervals.
It has been shown that newly formed periodontal tis-
sues in intrabony defects can be managed for ≥10 years 
[34]. It is unclear whether more frequent or meticulous 
supportive periodontal therapy could have prevented 
such CAL losses in the two patients. In a previous 
randomized clinical trial of the combination therapy, 
it was reported that poor oral hygiene, frequent BOP 
and infrequent maintenance visits did not seem to play 
a critical role in the long-term stability of the CAL 
gain [25]. However, patient compliance and appropri-
ate periodontal maintenance are generally considered 
to be important for long-term success of periodontal 
regenerative therapy [5]. We continue to provide care-
ful maintenance care to the participants in the present 
study.
There are several limitations of this study. First, the 
sample size was small and the data were from one insti-
tution. Second, the study was non-random and uncon-
trolled. A controlled, longitudinal study with larger 
sample size is needed to better evaluate the long-term 
performance of the combination therapy. Since periodon-
tal disease is a multifactorial disease, the use of multivari-
ate analysis would be more appropriate to analyse data 
from larger sample size. Also, it is not possible to confirm 
that periodontal regeneration had indeed occurred to the 
treated site, because no histological analysis can be pre-
sented. Lastly, the surgical procedures were performed by 
seven periodontists with various experience levels. This 
may have contributed to the differences in clinical out-
comes among the participants, as indicated by the high 
standard deviations.
Despite these limitations, the study findings add sig-
nificantly to the existing literature on the clinical effec-
tiveness of the combination regenerative therapies. The 
participants in the present study are currently being 
followed up to evaluate more longitudinal treatment 
outcomes.
Conclusions
The periodontal regenerative therapy using DBBM and 
CB produced significant clinical effects such as gain in 
CAL and reduction in PD, up to 2.5  years in the treat-
ment of intrabony defects. There was a trend for decrease 
in CAL gain over time. Further studies are required to 
determine the true benefit of and appropriate case selec-
tion for this combination therapy. Such information may 
contribute to the optimization of the periodontal regen-
erative therapy.
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